PACAP and PAC1 receptor expression in pancreatic ductal carcinoma.

PACAP and PAC1 receptor expression in pancreatic ductal carcinoma. Oncol Lett. 2019 Dec;18(6):5725-5730 Authors: Ferencz S, Reglodi D, Kaszas B, Bardosi A, Toth D, Vekony Z, Vicena V, Karadi O, Kelemen D Abstract Pancreatic carcinoma is one of the most malignant diseases and is associated with a poor survival rate. Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide that acts on three different G protein-coupled receptors: the specific PAC1 and the VPAC1/2 that also bind vasoactive intestinal peptide. PACAP is widely distributed in the body and has diverse physiological effects. Among other things, it acts as a trophic factor and influences proliferation and differentiation of several different cells both under normal circumstances and tumourous transformation. Changes of PACAP and its receptors have been shown in various tumour types. However, it is not known whether PACAP and its specific receptor are altered in pancreatic cancer. Perioperative data of patients with pancreas carcinoma was investigated over a five-year period. Histological results showed Grade 2 or Grade 3 adenocarcinoma in most cases. PACAP and PAC1 receptor expression were investigated by immunohistochemistry. Staining intensity of PAC1 receptor was strong in normal tissues both in the exocrine and endocrine parts of the pancreas, the receptor staining was markedly weaker in the adenocarcinoma. PACAP immunostaining was weak in the exocrine...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research